An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Nevirapine

DRUG

Zidovudine

Trial Locations (3)

35233

Cooper Green Hosp, Birmingham

921036325

Univ of California / San Diego Treatment Ctr, San Diego

01655

Univ of Massachusetts, Worcester

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00000649 - An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3) | Biotech Hunter | Biotech Hunter